Summary: Notice is hereby given that the Office of Research Integrity (ORI) and the Assistant Secretary for Health have taken final action in the following case:

Kristin Roovers, Ph.D., University of Pennsylvania: Based on an investigation conducted by the University of Pennsylvania (UP) and additional analysis and information obtained by the Office of Research Integrity during its oversight review, the U.S. Public Health Service (PHS) found that Kristin Roovers, Ph.D., former postdoctoral fellow, Departments of Medicine, Cell and Developmental Biology, and Pharmacology, and Howard Hughes Medical Institute, and former graduate student, Department of Pharmacology, UP, engaged in misconduct in science in research funded by National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), grants R01 HL061567, P50 HL057278, and T32 HL07873, National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, grants R01 DK52574 and R01 GM51878, National Cancer Institute (NCI), NIH, grant R01 CA72639, and National Institute of General Medical Sciences (NIGMS), NIH, grants R01 GM48824, R01 GM58224, R01 GM51878, and R01 GM69064.

Dr. Roovers’ manipulations and falsification of data were extensive, encompassing 19 panels of Western blot data, appearing in 11 figures in 3 publications from her research as a graduate student and her first postdoctoral position and in 9 panels of immunoblot data in 8 figures of an unpublished manuscript.

Specifically, the findings involved falsification by duplication and reuse of immunoblot data to misrepresent the results as data from different experiments that had been reported in the following manuscript and three publications:

- Figures 2C, 3C, 4D, 4E, 6C, 7B, and 8B in a
manuscript submitted to the Journal of Clinical Investigation entitled: “Akt1 promotes physiologic, but antagonizes pathologic, cardiac growth.”


Corrections were recommended by UP for the Nature Cell Biology paper.

Dr. Roovers’ falsified Western blot data from the publications in Nature Cell Biology and from Developmental Cell were included in NIH grant applications CA 72639–07 and GM 69064–01. ORI has implemented the following administrative actions for a period of five (5) years, beginning on June 7, 2007:

1. Dr. Roovers is debarred from eligibility for any contracting or subcontracting with any agency of the United States Government and from eligibility or involvement in nonprocurement programs of the United States Government referred to as “covered transactions” as defined in HHS’ implementation of OMB Guidelines to Agencies on Governmentwide Debarment and Suspension at 2 CFR part 376, et seq.; and
2. Dr. Roovers is prohibited from serving in any advisory capacity to PHS, including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant.

FOR FURTHER INFORMATION CONTACT:
Director, Division of Investigative Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453–8800.

Chris B. Pascal,
Director, Office of Research Integrity.
[FR Doc. E7–13703 Filed 7–13–07; 8:45 am]
BILLING CODE 4150–31–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention
[30Day–07–06BM]
Agency Forms Undergoing Paperwork; Reduction Act Review

The Centers for Disease Control and Prevention (CDC) publishes a list of

ESTIMATED ANNUALIZED BURDEN HOURS

<table>
<thead>
<tr>
<th>Type of respondents</th>
<th>Form name</th>
<th>Number of respondents</th>
<th>Number of responses per respondent</th>
<th>Average burden per response (in hours)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Women Seeking Health Care Services ..........</td>
<td>Eligibility Script for Pretest .................</td>
<td>70</td>
<td>1</td>
<td>1/60</td>
</tr>
<tr>
<td></td>
<td>Baseline Questionnaire for Pretest ...............</td>
<td>65</td>
<td>1</td>
<td>15/60</td>
</tr>
<tr>
<td></td>
<td>Follow-up Questionnaire Pretest ..................</td>
<td>59</td>
<td>1</td>
<td>12/60</td>
</tr>
<tr>
<td></td>
<td>Eligibility Script for Main Study ................</td>
<td>1,533</td>
<td>1</td>
<td>1/60</td>
</tr>
<tr>
<td></td>
<td>Baseline Questionnaire for Main Study ..........</td>
<td>1,227</td>
<td>1</td>
<td>17/60</td>
</tr>
<tr>
<td></td>
<td>Follow-up Questionnaire Main Study ..............</td>
<td>860</td>
<td>1</td>
<td>22/60</td>
</tr>
</tbody>
</table>

Dated: July 9, 2007.

Maryam I. Daneshvar,
Acting Reports Clearance Officer, Centers for Disease Control and Prevention.
[FR Doc. E7–13730 Filed 7–13–07; 8:45 am]
BILLING CODE 4150–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration
Agency Information Collection Activities: Submission for OMB Review; Comment Request

Periodically, the Substance Abuse and Mental Health Services Administration (SAMHSA) will publish a summary of information collection requests under OMB review, in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these documents, call the SAMHSA Reports Clearance Officer on (240) 276–1243.

Project: National Evaluation of the Protection and Advocacy for Individuals with Mental Illness (PAIMI) Program—NEW

In recognition that systematic evaluation of this and other government programs are part of good management...